Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to provide a more reasonable basis for clinical drug programs.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biotech Pharmaceutical Co., Ltd.
• Treatments: Nimotuzumab

Criteria

Inclusion Criteria:

1. Patients with histologically or cytologically confirmed nasopharyngeal carcinoma

2. Sex and age without limiting

3. Treatment without limiting

4. Subjects with reproductive potential (males and females) willing to use reliable means of contraception

5. Able and willing to give written informed consent and comply with the requirements of the study protocol

Exclusion Criteria:

1. Patients with severe allergies or idiosyncratic constitution

2. Women who are pregnant (determined by urine pregnancy test)or breast feeding

3. Any other severe complications or functional disorder of organ systems, which will affect the evaluation of safety of patients or will interfere with the test drug according to the researcher's point of view